The Road to Qualification of Novel Biomarkers in Type 1 Diabetes


The Critical Path Institute (C-Path) is hosting a meeting entitled “The Road to Qualification of Novel Biomarkers in Type 1 Diabetes”.

The planning committee which includes JDRF International, The Leona M. & Harry B. Helmsley Charitable Trust (Helmsley Trust), and Janssen Research & Development (Janssen), have been working together to form a new consortium that will work towards obtaining regulatory qualification for biomarkers of islet auto-immunity that can be used in the development of therapies for the treatment of Type 1 Diabetes (T1D). We are inviting your support and participation in the development of this new consortium.  As a member, your expertise will play a guiding role in defining the consortia’s focus and progression with our shared data forming the foundation of the qualification process.

The objective of the meeting will be to lay the groundwork for a collaborative effort while offering the opportunity to learn more about the consortium structure and scientific program.  Key leaders from the founding organizations, representatives from the major pharmaceutical companies, and the U.S. Food & Drug Administration will be participating. 


  • When

  • Monday, November 7, 2016
    12:00 PM - 5:00 PM
    Eastern Time Zone

  • Where

  • Tysons Corner Marriott
    8028 Leesburg Pike
    Tysons Corner, Virginia 22182

Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!